Bristol Urological Institute, Southmead Hospital, Bristol, BS10 5NB, UK.
Benign prostatic obstruction (BPO) affects an increasing number of men with age. It can cause troublesome lower urinary tract symptoms, can have a negative impact on quality of life, and may be associated with significant morbidity. Currently available medication and surgical treatments are limited by adverse events, invasiveness, and patient compliance. This has driven research into the pathogenesis of benign prostatic hyperplasia and led to the development of novel pharmacological agents and minimally invasive therapeutic interventions. This review highlights emerging treatment options for BPO.
Written by:
Parsons BA, Hashim H. Are you the author?
Reference: Curr Urol Rep. 2011 Aug;12(4):247-54.
doi: 10.1007/s11934-011-0190-4
PubMed Abstract
PMID: 21475952
UroToday.com BPH and Male LUTS Section
